APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation: COMMENT

被引：0
作者：
Kovacs, Michael J. [1 ]
Lazo-Langner, Alejandro [1 ]
机构：
[1] Western Univ, Dept Med, London, ON, Canada
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2021年 / 19卷 / 08期
关键词：
MOLECULAR-WEIGHT HEPARIN;
D O I：
10.1111/jth.15356
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2089 / 2089
页数：1
相关论文
共 4 条
  • [1] Kitchen S, 1999, THROMB HAEMOSTASIS, V82, P1289
  • [2] Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin
    Kovacs, MJ
    Keeney, M
    MacKinnon, K
    Boyle, E
    [J]. CLINICAL AND LABORATORY HAEMATOLOGY, 1999, 21 (01): : 55 - 60
  • [3] Monitoring unfractionated heparin therapy: Lack of standardization of anti-Xa activity reagents
    Smahi, Motalib
    De Pooter, Neila
    Hollestelle, Martine J.
    Toulon, Pierre
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (10) : 2613 - 2621
  • [4] Toulon P, 2021, J THROMB HAEMOST, V19, P2002, DOI 10.1111/jth.15264
1